Physician profile
Pedram Hamrah
NPI 1366483778
$186,913.28
in general payments reported to CMS, 2019-2025
26 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $8,701 · 2021: $30K · 2022: $7,054 · 2023: $56K · 2024: $46K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $111K · Honoraria: $5,594 · Travel and Lodging: $3,131 · Food and Beverage: $1,941 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $110,998.38 |
| Honoraria | $5,593.66 |
| Travel and Lodging | $3,131.42 |
| Food and Beverage | $1,941.05 |
| Education | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $96,236.99 | 2019-2025 | Oxervate |
| Sanofi-Aventis U.S. LLC | $13,878.15 | 2021 | |
| Kala Pharmaceuticals, INC. | $13,559.07 | 2019-2022 | |
| Sanofi US Services INC. | $12,649.86 | 2021 | |
| Dompe Farmaceutici S.P.A. | $10,000.00 | 2025 | |
| Amgen INC. | $8,988.49 | 2024 | Tepezza |
| Alcon Research LLC | $7,500.00 | 2024-2025 | Tryptyr |
| Axogen | $6,850.38 | 2024-2025 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector, Axoguard Nerve Cap |
| Horizon Therapeutics Plc | $4,241.99 | 2023 | Tepezza |
| Biotissue Holdings INC. | $3,724.23 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $2,120.25 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $1,611.44 | 2023-2024 | Eysuvis |
| Aerie Pharmaceuticals, INC. | $1,600.00 | 2019 | |
| Eyevance Pharmaceuticals LLC | $1,365.32 | 2019 | |
| Biogen, INC. | $648.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $396.76 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Novartis Pharmaceuticals Corporation | $394.85 | 2022-2023 | |
| Thea Pharma INC. | $367.74 | 2022-2025 | |
| Shire North American Group INC | $266.95 | 2019 | |
| Ocular Therapeutix, INC. | $148.60 | 2019 | |
| Oyster Point Pharma, INC. | $140.46 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $135.04 | 2019 | |
| Sun Pharmaceutical Industries INC. | $76.66 | 2019-2023 | Cequa |
| Allergan, INC. | $12.05 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Hamrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.